SRPT Jan 2025 200.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 03:14PM EDT. Market open.
| Previous Close | 9.09 |
| Open | 9.20 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 200.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 8.90 - 9.35 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
Investor's Business DailySarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval
Sarepta Therapeutics had its Relative Strength (RS) Rating upgraded from 68 to 95 Monday. The biotech soared 30% Friday on positive news on its Duchenne Muscular Dystrophy gene therapy. Decades of market research shows that the best stocks often have an 80 or better RS Rating as they begin their biggest runs.
ZacksSarepta Therapeutics (SRPT) Soars 30.1%: Is Further Upside Left in the Stock?
Sarepta Therapeutics (SRPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
© 2024 Yahoo. All rights reserved.